Carbapenamases in antibiotic resistance
Download
1 / 53

Carbapenamases in Antibiotic Resstance - PowerPoint PPT Presentation


  • 2691 Views
  • Uploaded on

Carbapenamases in Antibiotic Reistance

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Carbapenamases in Antibiotic Resstance' - doctorrao


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Carbapenamases in antibiotic resistance

Carbapenamases in Antibiotic Resistance

Dr.T.V.Rao MD


What are carbapenems
What are ResistanceCarbapenems

  • Carbapenems are a class of beta-lactam antibiotics with a broad spectrum of antibacterial activity. They have a structure that renders them highly resistant to beta-lactamases. Carbapenems antibiotics were originally developed from thienamycin, a naturally-derived product of Streptomyces cattleya


Carbapenems structure
Carbapenems - Structure Resistance

  • Carbapenems are structurally very similar to the pencillins, but the sulfur atom in position 1 of the structure has been replaced with a carbon atom, and hence the name of the group, the carbapenems.


Drugs belong to the carbapenem class
Drugs belong to the carbapenem class Resistance:

  • Imipenem

  • Meropenem Ertapenem Doripenem Panipenem/ betamipron Biapenem


Background of carbapenamases
Background of Carbapenamases Resistance

  • Carbapenem-resistant Enterobacteriaceae (CRE) are usually resistant to all β-lactam agents as well as most other classes of antimicrobial agents. The treatment options for patients infected with CRE are very limited. Healthcare-associated outbreaks of CRE have been reported


Discovery of carbapenamases
Discovery of Carbapenamases Resistance

  • In 1996, the first isolate of KPC-producing bacteria was discovered in a clinical specimen of K pneumoniae from a hospital in North Carolina involved in the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) surveillance program. KPCs were infrequently isolated until 2001, when KPC-producing Enterobacteriaceae were reported in several extended outbreaks in metropolitan hospitals of New York and New Jersey.


Carbapenemases are produced by several commonly infecting gram negative bacteria
Carbapenemases are produced by several commonly infecting Gram Negative Bacteria

  • Carbapenemases are known to exist in several different species of gram-negative bacilli including species of Enterobacteriaceae and Pseudomonas aeruginosa. However, carbapenemases are more common in lactose-fermenting species of Enterobacteriaceae (e.g., K. pneumoniae and E. coli) than in non-lactose fermenting Enterobacteriaceae (e.g. Serratia marcescens and some Enterobactericae spp.) and P. aeruginosa.


How carbapenamase resistance is initiated
How Carbapenamase resistance is initiated Gram Negative Bacteria

  • Carbapenem resistance in Enterobacteriaceae occurs when an isolate acquires a carbapenemase or when an isolate produces an extended-spectrum cephalosporinase, such as an AmpC-type β-lactamase, in combination with porin loss. In the United States, the most common mechanism of carbapenem resistance is the Klebsiella pneumoniae carbapenemase (KPC).


Carbapenamases a global problem
Carbapenamases a Global Problem Gram Negative Bacteria

  • The resistance to Carbapenems has emerged worldwide and the predominant mechanism of resistance is attributed by the production of various Carbapenems-hydrolyzing β-lactamases referred as Carbapenamases


Carbapenems used as important life saving option
Carbapenems used as important life saving option Gram Negative Bacteria

  • Carbapenems are often used as antibiotics of last resort for treating infections due to multidrug-resistant gram-negative bacilli, because they are stable even in response to extended-spectrum and AmpC β-lactamases. However, gram-negative bacilli producing the acquired metallo-β-lactamases (MBLs) IMP and VIM have been increasingly reported in Asia and Europe and more recently, they have been detected in Canada and the United States


Carbapenem resistance mechanisms
Carbapenem Resistance: Mechanisms Gram Negative Bacteria


Transposons and integrons contribute for spread of resistance
Transposons and Gram Negative BacteriaIntegrons contribute for spread of resistance,

  • The genes of these MBL enzymes are often plasmid borne and are associated with mobile genetic elements (transposons and integrons), making them readily transferable among various species


Carbapenamases
Carbapenamases Gram Negative Bacteria


Carbapenamases are complex in mechanisims
Carbapenamases are complex in Mechanisims Gram Negative Bacteria

  • Carbapenamases constitute the most versatile family of β-lactamases belonging to molecular classes A, B and D and are capable of hydrolyzing almost all β-lactams. Given their zinc dependent hydrolytic activity, Carbapenamases of class B is designated as metallo-ß-lactamases (MBL) that include, for example, IMP, GIM, SIM, SPM, and VIM carbapenemases, and these MBL enzymes have been reported in P.aeruginosa and other multidrug resistant pathogens


Carbapenamases are spreading faster
Carbapenamases are spreading faster Gram Negative Bacteria

  • A new class of bacterial enzymes capable of inactivating Carbapenems, known as Klebsiella pneumoniae Carbapenamases (KPCs), has rapidly spread in the United States and continues to be extensively reported elsewhere in the world. KPCs are class A Carbapenamases that reside on transferable plasmids and can hydrolyze all pencillins, cephalosporins, and Carbapenems.


Klebsiella pneumoniae carbapenamases
Klebsiella pneumoniae Gram Negative Bacteria Carbapenamases

  • KPC-producing organisms continues to evolve. Although most KPCs are detected in isolates of Klebsiella and Escherichia coli, KPCs have been extensively reported in other genera of the Enterobacteriaceae family, such as Proteus,Serratia, Salmonella, and Citrobacter.


Klebsiella pneumoniae Gram Negative Bacteria Carbapenamases

  • Located on plasmids; conjugative and nonconjugative

  • blaKPC is usually flanked by transposon sequences

  • blaKPC reported on plasmids with:

    • Normal spectrum b-lactamases

    • Extended spectrum b-lactamases

    • Aminoglycoside resistance


Emerging carbapenem resistance in gram negative bacilli
Emerging Carbapenem Resistance in Gram-Negative Bacilli Gram Negative Bacteria

  • Significantly limits treatment options for life-threatening infections

  • No new drugs for gram-negative bacilli

  • Emerging resistance mechanisms, carbapenemases are mobile,

  • Detection of carbapenemases and implementation of infection control practices are necessary to limit spread


Kpc s in enterobacteriaceae
KPC’s in Gram Negative BacteriaEnterobacteriaceae

Pseudomonas aeruginosa – Columbia & Puerto Rico


Pseudomonas aeruginosa carbapenamases
Pseudomonas aeruginosa Gram Negative BacteriaCarbapenamases

  • KPC resistance has been reported in inherently resistant organisms such as Pseudomonasfrom Trinidad, an isolate of multidrug-resistant Pseudomonas aeruginosa that harboured a novel KPC-6 gene was detected.


Special antibiotic sensitivity testing is emerging need in microbiology laboratories
Special antibiotic sensitivity testing is emerging need in Microbiology laboratories

  • Supplemental testing, in addition to the routine susceptibility tests of isolates, has become necessary in order to detect the deluge of beta-lactamases and carbapenemases that clinical laboratories face today


When to suspect a kpc producers
When to Suspect a Microbiology laboratoriesKPC-Producers

  • Enterobacteriaceae – especially Klebsiella pneumoniae that are resistant to extended-spectrum cephalosporins:

    • MIC range for 151 KPC-producing isolates

      • Ceftazidime 32 to >64 mg/ml

      • Ceftriaxone ≥ 64 mg/ml

      • Cefotaxime ≥ 64 mg/ml

    • Variable susceptibility to cefoxitin and cefepime


Modified Hodge Test for Carbapenemase Detection in Microbiology laboratoriesEnterobacteriaceae


The modified hodge test
The Modified Hodge Test Microbiology laboratories

The Modified Hodge Test is a phenotypic confirmatory test for “Carapnemase” activity and is indicated when there is a positive screening test and resistance to one or more agents in cephalosporin subclass III (i.e., cefoperazone, cefotaxime, ceftazidime, ceftizoxime, and ceftriaxone) Be aware that imipenem disk tests perform poorly as a screen for carbapenemases.


Clsi recommends
CLSI Recommends Microbiology laboratories

  • CLSI Recommends doing Modified Hodge test before reporting Carbapenam susceptibility results if results are elevated but susceptible to Carbapenam by Minimum inhibitory concentration.

  • The results of intermediate or resistance to Carbapenems need not be tested with MHT


The modified hodge test mht
The Modified Hodge Test (MHT) Microbiology laboratories

  • The Modified Hodge Test (MHT) detects carbapenemase production in isolates of Enterobacteriaceae

  • Carbapenemase production is detected by the MHT when the test isolate produces the enzyme and allows growth of a carbapenem susceptible strain (E.coli ATCC 25922) towards a carbapenem disk


The carapnemase is detected by antibiotic sensitivity patterns
The Carapnemase is detected by antibiotic sensitivity patterns

  • Carbapenemase production is detected by the MHT when the test isolate produces the enzyme and allows growth of a carbapenem susceptible strain (E.coli ATCC 25922) towards a carbapenem disk. The result is a characteristic cloverleaf-like indentation


Step 1 and 2 of mht
Step 1 and 2 of MHT patterns

  • Prepare a 0.5 McFarland dilution of the E.coli ATCC 25922 in 5 ml of broth or saline.

  • Dilute 1:10 by adding 0.5 ml of the 0.5 McFarland to 4.5 ml of MHB or saline.


Step 3 and 4 of mht
Step 3 and 4 of MHT patterns

  • Streak a lawn of the 1:10 dilution of E.coli ATCC 25922 to a Mueller Hinton agar plate and allow to dry 3–5 minutes.

  • Place a 10 μg meropenem or ertapenem susceptibility disk in the center of the test area.




Step 5 and 6 of mht
Step 5 and 6 of MHT patterns

  • In a straight line, streak test organism from the edge of the disk to the edge of the plate. Up to four organisms can be tested on the same plate with one drug.

  • Incubate overnight at 35OC ± 2OC in ambient air for 16–24 hours


Modified hodge test
Modified Hodge Test patterns

Lawn of E. coli ATCC 25922

1:10 dilution of a

0.5 McFarland suspension

Test isolates

Imipenem disk

Described by Lee et al. CMI, 7, 88-102. 2001.


Observation for carbapenamases detection by hmt
Observation for Carbapenamases detection by HMT patterns

  • After 16–24 hours of incubation, examine the plate for a clover leaf-type indentation at the intersection of the test organism and the E. coli 25922, within the zone of inhibition of the carbapenem susceptibility disk.


Mht detection photo courtesy of cdc
MHT detection patterns(photo courtesy of CDC)

  • The MHT performed on a 100 mm MHA plate. (1) K. pneumoniaeATCC BAA 1705, positive result K. pneumoniaeATCC BAA 1706, negative result; and a clinical isolate, positive result312


A positive hmt test
A Positive HMT test patterns

  • MHT Positive test has a clover leaf-like indentation of the E.coli 25922 growing along the test organism growth streak within the disk diffusion zone.

  • A positive MHT indicates that this isolate is producing a carbapenemase


A negative hmt test
A negative HMT Test patterns

  • MHT Negative test has no growth of the E.coli 25922 along the test organism growth streak within the disc diffusion.

  • A negative MHT indicates that this isolate is not producing a carbapenemase


Quality control strains in modified hodge test
Quality control strains in Modified Hodge test patterns

  • Perform quality control of the Carbapenems disks according to CLSI guidelines.

  • Perform quality control with each run.

  • MHT Positive Klebsiella pneumoniae ATCC BAA-1705

  • MHT Negative Klebsiella pneumoniae ATCC BAA-1706


Clsi guidelines for carbapenamases detection
CLSI guidelines for Carbapenamases detection patterns

  • CLSI has published guidelines for detection of isolates producing carbapenemases (CLSI document M100) . For isolates that test susceptible to a carbapenem but demonstrate reduced susceptibility either by disk diffusion or MIC testing, performing a phenotypic test for carbapenemase activity, the Modified Hodge Test (MHT), is recommended


Testing with ertapenem or meropenem
Testing with ertapenem or meropenem patterns

  • The procedure described by Landman et al. describes using a 10-μg imipenem disk for step 1. However, there are species of Enterobacteriaceae which have intrinsic mechanisms of resistance to imipenem other than a carbapenemase (See CLSI document M100, Appendix G). Therefore, ertapenem or meropenem may provide more specific selection for acquired carbapenem resistance in Enterobacteriaceae


New CLSI guidelines patterns Nonsusceptible ”Interpretive Category”


Nonsusceptible interpretive category
patternsNonsusceptible”Interpretive Category

  • “…. used for organisms that have only a susceptible interpretive category, but not intermediate or resistant interpretive categories (ie, susceptible-only interpretive category). A susceptible-only interpretive category may be applied to new antimicrobial agents for which no resistant isolates have been encountered at the time the initial interpretive criteria are determined.


Nonsusceptible interpretive category1
Nonsusceptible” patternsInterpretive Category

  • The isolates that test with an MIC above the susceptible interpretive breakpoint are designated as nonsusceptible. A designation of nonsusceptible does not necessarily mean that a resistance mechanism exists in the isolate. The MIC of the isolate in the nonsusceptible range may be within the previously recognized wild-type distribution of susceptibility results; however, there is limited clinical experience with these isolates in clinical trials.”


Interpretation results conveyed to infection control departments
Interpretation/Results patternsConveyed to Infection Control Departments

  • Report all cultures that are positive for CRE or carbapenemase-producing Enterobacteriaceae to the appropriate infection control personnel.


Patients infected will be dealt with caution to prevent spread
Patients infected will be dealt with caution to prevent spread

  • patients colonized with carbapenem-resistant or Carbapenamases-producing Enterobacteriaceae in the intestinal tract and the Patients who grow these organisms should be placed on Contact Precautions to prevent transmission of the resistant bacteria


Laboratories should create protocols for detection of cre
Laboratories should create protocols for detection of CRE spread

  • The exact procedure for confirmation of CRE or carbapenemase-production should be laboratory-specific and chosen based upon laboratory workflow and the types of isolates causing clinical infections in the patient population served. It may be helpful to refer to the CLSI guidelines for identification of carbapenemase production in isolates that test susceptible to Carbapenems


Follow contact precautions
Follow contact Precautions spread

  • Contact Precautions should be implemented for all patients with positive cultures for CRE or carbapenemase-producing Enterobacteriaceae



Care of the patients colonized with carapnemase resisistant enterobactericae
Care of the patients colonized with Carapnemase resisistant Enterobactericae

  • Patients colonized with CRE are thought to be a source of transmission in the healthcare setting . Identifying patients who are colonized with CRE and placing these patients in isolation precautions may be an important step in preventing transmission


Detection of antibiotic resistance patterns is more than past
Detection of Antibiotic resistance patterns is more than past

  • Resistance to our beta-lactam and carbapenem antibiotics is becoming daunting for antimicrobial therapy for infections involving the Enterobacteriaceae. Similarly, laboratory testing to detect these resistance mechanisms is becoming more complex and perplexing for microbiology laboratories.


Automation has limited use in carbapenamases detection
Automation has limited use in Carbapenamases detection past

  • Automated testing alone will not detect all of the resistance patterns that occur via beta-lactamases and carbapenemases. Failure to detect organisms with these enzymes can result in erroneous reports that would indicate an isolate is susceptible to beta-lactam and/or carbapenem antibiotics.


Detection of drug resistance helps to control the spread of hospital acquired infections
Detection of Drug resistance helps to control the spread of Hospital acquired infections

  • In addition to the risk of compromised care of the patient, when pathogens with these enzymes go undetected, necessary infection control measures are precluded, thereby allowing the risk of these resistant organisms becoming endemic in a hospital environment



ad